Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Nutex Health Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-2.8% vs price
Base Case (Median)
111.1% vs price
Bull Case (75th pct.)
223.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $436.88 | 111.1% | High (40%) |
| PE Comparable | $678.74 | 227.9% | Medium (25%) |
| Growth Trajectory DCF | $660.43 | 219.0% | Medium (20%) |
| Graham Number | $167.48 | -19.1% | Low (10%) |
| EV/EBITDA | $234.99 | 13.5% | Medium (20%) |
| EV/FCF | $774.04 | 273.9% | Medium (20%) |
| Earnings Power Value | $105.06 | -49.2% | Medium (50%) |
Based on 7 out of 7 methods, NUTX appears fairly valued at the current price of $207.00. The base case fair value of $436.88 implies 111.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.